Search Results

Grifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration for Yimmugo®, an innovative intravenous immunoglobulin therapeutic, to treat primary immunodeficiencies.

Grifols, one of the world’s leading producers of plasma-derived medicines, announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin Yimmugo® during the next seven years, following recent Food and Drug Administration approval to treat primary immunodeficiencies.

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has completed the sale of a 20% equity stake in Shanghai RAAS to Haier Group Corporation and forged a strategic alliance with Haier Group.

Grifols, S.A., a global healthcare company and leading manufacturer of plasma-derived medicines, announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission.

Grifols announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate, BT524, advance this potential treatment for acquired fibrinogen deficiency, an underserved growth market.

Grifols announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation, the first for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.

The blood plasma pharma is considering a buyout offer from the founding family and asset manager Brookfield, which would delist the company from the Spanish and Nasdaq markets.